From the SEC filing from Acadia (my formatting):
In addition, pursuant to the License Agreement, Neuren granted to the Company a worldwide, exclusive license to develop and commercialize any product developed by or on behalf of Neuren or the Company containing a NNZ-2591 compound as an active ingredient (a “NNZ-2591 Product”) for the treatment of Rett syndrome and Fragile X syndrome (the “Acadia NNZ-2591 Field”). Neuren may conduct development and commercialization of NNZ-2591 outside of the Acadia NNZ-2591 Field.
Ann: Q2 2023 quarterly activity and cash flow report, page-10
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.21 |
Change
-0.130(0.85%) |
Mkt cap ! $1.944B | |||
| Open | High | Low | Value | Volume |
| $15.19 | $15.47 | $15.07 | $6.450M | 422.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1938 | $15.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.29 | 54 | 1 |
View Market Depth
| Last trade - 16.10pm 29/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |